{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with Parkinson disease (PD), with the G2019S mutation being the most prevalent, showing increased kinase activity suggesting a gain-of-function mechanism.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, linking LRRK2 mutations to PD through increased kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses in vitro kinase assays to measure LRRK2's kinase activity towards MKKs, which are relevant to the disease mechanism involving MAP kinase signalling pathways.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (kinase activity assay) effectively models the disease pathogenesis by measuring the impact of LRRK2 mutations on kinase activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes controls (wild-type LRRK2 and kinase dead variant LRRK2 K1906M) and replicates (at least four independent data points for each mutant).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were used, meeting the criteria for proceeding to evaluate variant controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the kinase activity of LRRK2 G2019S to wild-type LRRK2 and other PD-associated variants (R1441C, I2020T), demonstrating increased activity for G2019S.",
          "judgment": "Yes",
          "reasoning": "Variant controls (wild-type and other PD-associated variants) were used, showing differential kinase activity that supports the pathogenic nature of G2019S.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses (ANOVA and Tukey's post-hoc test) were performed, showing significant increases in kinase activity for G2019S compared to wild-type.",
          "judgment": "Yes",
          "reasoning": "The statistical analyses support the increased kinase activity of G2019S, correlating with its pathogenic effect.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The study reports a 3-4-fold increase in kinase activity for G2019S compared to wild-type, indicating a strong pathogenic effect.",
          "judgment": "Yes",
          "reasoning": "The significant increase in kinase activity suggests a high OddsPath, supporting a strong pathogenic effect.",
          "next_step_or_outcome": "Assign PS3_very_strong"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The LRRK2 G2019S variant shows a significant increase in kinase activity, supported by robust experimental and statistical evidence, leading to a PS3_very_strong rating for pathogenic evidence."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with Parkinson disease (PD), with some mutations showing increased kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism, linking LRRK2 mutations to PD through altered kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses in vitro kinase assays to measure LRRK2's kinase activity towards MKKs, relevant to the disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The assay class is appropriate for modeling the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Controls and replicates were used, including wild-type LRRK2 and kinase dead variant.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included, meeting criteria for further evaluation.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares I2020T to wild-type and other variants, showing a slight but significant increase in kinase activity.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used, showing differential activity that supports a pathogenic effect.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses show a significant increase in kinase activity for I2020T compared to wild-type.",
          "judgment": "Yes",
          "reasoning": "Statistical support for increased kinase activity is present.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study reports a 1.5-fold increase in kinase activity for I2020T, indicating a moderate pathogenic effect.",
          "judgment": "Yes",
          "reasoning": "The increase in activity is significant but moderate, suggesting a supporting level of pathogenic evidence.",
          "next_step_or_outcome": "Assign PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 I2020T variant shows a slight but significant increase in kinase activity, supported by experimental evidence, leading to a PS3_supporting rating for pathogenic evidence."
    }
  ]
}